GeneDx Holdings (WGS) Payables (2020 - 2026)

GeneDx Holdings has disclosed Payables across 7 years of filings, most recently posting $46.6 million for Q1 2026.

• In Q1 2026, Payables rose 11.23% year-over-year to $46.6 million; the TTM figure through Mar 2026 stood at $46.6 million (up 11.23% YoY), while the FY2025 annual figure was $57.6 million, up 86.05% from the prior year.
• Payables declined to $46.6 million in Q1 2026, from $57.6 million in the prior quarter.
• Over the last five years, Payables for WGS reached as high as $115.9 million in Q2 2022 and fell as low as $31.0 million in Q4 2024.
• The 5-year median for Payables is $52.0 million (2024), against an average of $57.3 million.
• Annual changes were most pronounced in 2022 — Payables surged 156.19% — and 2023, when it plunged 55.87%.
• A 5-year view of Payables shows it stood at $84.9 million in 2022, then plunged by 55.87% to $37.5 million in 2023, then fell by 17.28% to $31.0 million in 2024, then surged by 86.05% to $57.6 million in 2025, then retreated by 19.23% to $46.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $46.6 million, $57.6 million, and $50.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.